ATE551365T1 - Il-1-alpha für den einsatz in einem verfahren zur behandlung von atherosklerotischen plaques. - Google Patents

Il-1-alpha für den einsatz in einem verfahren zur behandlung von atherosklerotischen plaques.

Info

Publication number
ATE551365T1
ATE551365T1 AT07734572T AT07734572T ATE551365T1 AT E551365 T1 ATE551365 T1 AT E551365T1 AT 07734572 T AT07734572 T AT 07734572T AT 07734572 T AT07734572 T AT 07734572T AT E551365 T1 ATE551365 T1 AT E551365T1
Authority
AT
Austria
Prior art keywords
disease
treatment
mammal
alpha
procedure
Prior art date
Application number
AT07734572T
Other languages
English (en)
Inventor
John Simard
Original Assignee
Xbiotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xbiotech Inc filed Critical Xbiotech Inc
Application granted granted Critical
Publication of ATE551365T1 publication Critical patent/ATE551365T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compositions Of Oxide Ceramics (AREA)
AT07734572T 2006-05-15 2007-05-15 Il-1-alpha für den einsatz in einem verfahren zur behandlung von atherosklerotischen plaques. ATE551365T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80002906P 2006-05-15 2006-05-15
PCT/IB2007/001264 WO2007132338A2 (en) 2006-05-15 2007-05-15 IL-1α IMMUNIZATION INDUCES AUTOANTIBODIES PROTECTIVE AGAINST ATHEROSCLEROSIS

Publications (1)

Publication Number Publication Date
ATE551365T1 true ATE551365T1 (de) 2012-04-15

Family

ID=38694276

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07734572T ATE551365T1 (de) 2006-05-15 2007-05-15 Il-1-alpha für den einsatz in einem verfahren zur behandlung von atherosklerotischen plaques.

Country Status (9)

Country Link
US (1) US20090191149A1 (de)
EP (1) EP2021033B1 (de)
JP (1) JP2009537507A (de)
CN (1) CN101448528A (de)
AT (1) ATE551365T1 (de)
AU (1) AU2007251239B2 (de)
CA (1) CA2652274A1 (de)
ES (1) ES2384278T3 (de)
WO (1) WO2007132338A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2617637C (en) * 2005-08-02 2017-07-18 Xbiotech Inc. Diagnosis, treatment, and prevention of vascular disorders using il-1.alpha. autoantibodies
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
US20100040574A1 (en) * 2006-05-22 2010-02-18 Xbiotech Inc. TREATMENT OF CANCER WITH ANTI-IL-1alpha ANTIBODIES
EP2285409B1 (de) 2008-05-30 2016-04-20 XBiotech, Inc Il-1-alpha-antikörper
CA2737056C (en) * 2008-09-12 2018-10-30 Xbiotech Inc. Targeting pathogenic monocytes
EP2569640A1 (de) 2010-05-12 2013-03-20 The University of Birmingham Biomarker
EP2582391B1 (de) 2010-06-18 2018-10-03 XBiotech, Inc Arthritis-behandlung
KR101910760B1 (ko) 2010-08-23 2018-10-22 엑스바이오테크, 인크. 종양성 질병들에 대한 치료
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
CN108404127B (zh) 2011-09-23 2025-12-12 埃克斯生物科技公司 恶病质治疗
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
JP6456015B2 (ja) * 2013-07-19 2019-01-23 国立大学法人三重大学 閉塞性動脈硬化症モデル動物、るい痩研究用モデル動物、及び全身性アミロイドーシスモデル動物としての非ヒト哺乳動物
CN105175503A (zh) * 2015-09-08 2015-12-23 苏州普罗达生物科技有限公司 因子viii抑制多肽及其应用
CN105175504A (zh) * 2015-09-08 2015-12-23 苏州普罗达生物科技有限公司 血管性血友病因子抑制多肽及其应用
EP3582813A4 (de) 2017-02-16 2020-12-30 XBiotech, Inc Behandlung von hidradenitis suppurativa
US10975146B2 (en) 2018-06-29 2021-04-13 Cedars-Sinai Medical Center Interleukin-1 inhibition for combination treatment of pancreatic cancer
CA3095740A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin alpha (il-1a)
CA3095679A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleuken 1 alpha (il-1a)
CA3095675A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095676A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9802402D0 (sv) * 1998-07-03 1998-07-03 Karolinska Innovations Ab Method of diagnosing cardiovascular disease and early atherosclerosis
US6555579B2 (en) * 1998-08-13 2003-04-29 The Wistar Institute Methods for reducing atherosclerotic plaques
US20030040617A9 (en) * 1999-03-12 2003-02-27 Rosen Craig A. Nucleic acids, proteins and antibodies
US20030232054A1 (en) * 2000-01-25 2003-12-18 Tang Y. Tom Novel nucleic acids and polypeptides
US20030026806A1 (en) * 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US20040224893A1 (en) * 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
CA2617637C (en) 2005-08-02 2017-07-18 Xbiotech Inc. Diagnosis, treatment, and prevention of vascular disorders using il-1.alpha. autoantibodies
NZ566971A (en) * 2005-09-28 2011-06-30 Cytos Biotechnology Ag Vaccine containing a virus like particle linked with an interleukin-1 molecule
EP2285409B1 (de) * 2008-05-30 2016-04-20 XBiotech, Inc Il-1-alpha-antikörper
CA2737056C (en) * 2008-09-12 2018-10-30 Xbiotech Inc. Targeting pathogenic monocytes

Also Published As

Publication number Publication date
AU2007251239A1 (en) 2007-11-22
ES2384278T3 (es) 2012-07-03
WO2007132338A3 (en) 2008-06-12
JP2009537507A (ja) 2009-10-29
EP2021033B1 (de) 2012-03-28
CA2652274A1 (en) 2007-11-22
US20090191149A1 (en) 2009-07-30
EP2021033A2 (de) 2009-02-11
EP2021033A4 (de) 2010-02-24
WO2007132338A2 (en) 2007-11-22
CN101448528A (zh) 2009-06-03
AU2007251239B2 (en) 2013-08-22

Similar Documents

Publication Publication Date Title
ATE551365T1 (de) Il-1-alpha für den einsatz in einem verfahren zur behandlung von atherosklerotischen plaques.
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
ATE464323T1 (de) Zusammensetzungen und verfahren für die tumor- diagnose und behandlung
NO20075527L (no) Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
EA201790087A1 (ru) Ковалентно связанные диатела, обладающие иммунореактивностью с pd-1 и lag-3, и способы их применения
MX388989B (es) Biomarcadores basados en sangre para diagnosticar enfermedad de arteria coronaria ateroesclerótica.
CR20110118A (es) Tratamiento de enfermedades autoinmunes e inflamatorias
TN2019000099A1 (en) Anti-lag-3 antibodies and compositions
EA201270767A1 (ru) Терапия на основе лигандов хемосенсорных рецепторов
UY31816A (es) Agente para el tratamiento y/o prevención de una enfemedad autoinmune y para la formación de células t reguladoras
EP4144367C0 (de) Verfahren zur behandlung von durch cd47 vermittelter phagozytose
DE602006018583D1 (de) Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
EA201590833A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
WO2016012285A3 (en) Method
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
UA104663C2 (xx) Антитіло, що зв'язує cd127$антитело, связывающее cd127
DE602006017109D1 (de) Nanopartikel und verfahren zur sol-gel-verarbeitung
MX357708B (es) Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
EP2544703A4 (de) Verfahren zur behandlung von gefässentzündungserkrankungen
WO2015013508A3 (en) Methods for diagnosing and treating immune disease
EA200701995A1 (ru) Способы уменьшения кальцификации
EP4297768A4 (de) Biomarker zur behandlung von interstitieller lungenerkrankung
MA34291B1 (fr) Compositions et méthodes de diagnostic et de traitement d'une tumeur
NO20080781L (no) GLEPP-inhibitorer i behandlingen av autoimmune og/eller inflammatoriske sykdommer